Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion

Diabetes Technology and Therapeutics

Volumn 19, Issue 1, 2017, Pages 25-33

  Bode, Bruce W ^a   Johnson, Joseph A ^a   Hyveled, Liselotte ^b   Tamer, Søren C ^b   Demissie, Marek ^b  

^a ATLANTA DIABETES ASSOCIATES   (United States)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Continuous glucose monitoring; Continuous subcutaneous insulin infusion; Insulin pump; Meal test; Postprandial plasma glucose; Type 1 diabetes

Indexed keywords

GLUCOSE; INSULIN ASPART; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EXPLORATORY RESEARCH; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE SENSOR; GLYCEMIC CONTROL; HEMATOMA; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INJECTION SITE NODULE; INJECTION SITE PAIN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; MALE; MIDDLE AGED; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TEST MEAL; BLOOD; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; METABOLISM; POSTPRANDIAL STATE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, SUBCUTANEOUS; INSULIN ASPART; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; TREATMENT OUTCOME;

EID: 85010008881     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2016.0350     Document Type: Article

References (28)

1. Luijf YM, van Bon AC, Hoekstra JB, et al.: Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes. Diabetes Care 2010;33:2152-2155.
2. Lilly E: Humalog(insulin lispro): Summary of Product Characteristics [article online]. www.ema.europa.eu/docs/enGB/documentlibrary/EPAR-ProductInformation/human/000088/WC500050332.pdf (accessed August 4, 2016).
3. Novo Nordisk. NovoRapid(insulin aspart): Summary of Product Characteristics [article online]. www.ema.europa.eu/docs/enGB/documentlibrary/EPAR-ProductInformation/human/000258/WC500030372.pdf (accessed August 4, 2016).
4. Sanofi-aventis. Apidra(insulin glulisine): Summary of Product Characteristics [article online]. www.ema.europa.eu/docs/enGB/documentlibrary/EPAR-ProductInformation/human/000557/WC500025250.pdf (accessed August 4, 2016).
5. Owens DR, Zinman B, Bolli GB: Insulins today and beyond. Lancet 2001;358:739-746.
6. Cobry E, McFann K, Messer L, et al.: Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. Diabetes Technol Ther 2010;12:173-177.
7. Scaramuzza AE, Iafusco D, Santoro L, et al.: Timing of bolus in children with type 1 diabetes using continuous subcutaneous insulin infusion (TiBoDi Study). Diabetes Technol Ther 2010;12:149-152.
8. Heinemann L, Muchmore DB: Ultrafast-acting insulins: state of the art. J Diabetes Sci Technol 2012;6:728-742.
9. Derosa G, Maffioli P, D'Angelo A, et al.: Effects of insulin therapy with continuous subcutaneous insulin infusion (CSII) in diabetic patients: comparison with multi-daily insulin injections therapy (MDI). Endocr J 2009;56:571-578.
10. Misso ML, Egberts KJ, Page M, et al.: Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev 2010:CD005103.
11. Pickup JC, Sutton AJ: Severe hypoglycemia and glycemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008;25:765-774.
12. Equality 1 Study Group-Evaluation of QUALITY of Life and Costs in Diabetes Type 1; Nicolucci A, Maione A, Franciosi M, et al. Quality of life and treatment satisfaction in adults with Type 1 diabetes: a comparison between continuous subcutaneous insulin infusion and multiple daily injections. Diabet Med 2008;25:213-220.
13. Monami M, Lamanna C, Marchionni N, Mannucci E: Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis. Acta Diabetol 2010;47 (Suppl 1):77-81.
14. Bode BW, Strange P: Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. Diabetes Care 2001;24:69-72.
15. Lepore G, Tommaselli L: Subcutaneous insulin pump. In: Bruttomesso D, Grassi G, eds. Technological Advances in the Treatment of Type 1 Diabetes. Basel: Karger, 2015, Vol. 24, pp. 128-142.
16. Miller KM, Foster NC, Beck RW, et al.: Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care 2015;38: 971-978.
17. James ML, Green L, Amiel SA, et al.: Evaluation of the effect of carbohydrate intake on postprandial glucose in patients with type 1 diabetes treated with insulin pumps. J Diabetes Sci Technol 2016;10(6):1287-1293.
18. El-Khatib FH, Russell SJ, Nathan DM, et al.: A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med 2010;2:27-27.
19. Luijf YM, DeVries JH, Zwinderman K, et al.: Day and night closed-loop control in adults with type 1 diabetes: a comparison of two closed-loop algorithms driving continuous subcutaneous insulin infusion versus patient selfmanagement. Diabetes Care 2013;36:3882-3887.
20. Russell SJ, El-Khatib FH, Nathan DM, et al.: Blood glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas. Diabetes Care 2012;35:2148-2155.
21. Food and Drug Administration (FDA). Inactive Ingredient Search for Approved Drug Products [database online], April 2016. www.accessdata.fda.gov/scripts/cder/iig/getiig WEB.cfm (accessed August 4, 2016).
22. Buckley ST, Kildegaard J, Høiberg-Nielsen R, et al.: Mechanistic analysis into the mode of action of niacinamide in faster-acting insulin aspart. Diabetes Technol Ther 2016:A291.
23. Heise T, Zijlstra E, Nosek L, Rikte T, et al.: Pharmacological properties of faster-acting insulin aspart versus insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: a randomised, double-blind, crossover trial. Diabetes Obes Metab 2016; doi:10.1111/dom.12803.
24. World Medical Association. WMA Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects-Last amended by the 64th WMA General Assembly, Fortaleza 2013. www.wma.net/en/30publications/10policies/b3 (accessed August 4, 2016).
25. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICHHarmonised Tripartite Guideline. Guideline for Good Clinical Practice. E6(R1) 10 June 1996. www.ema .europa.eu/docs/enGB/documentlibrary/Scientificguideline/2009/09/WC500002874.pdf (accessed August 4, 2016).
26. Seaquist ER, Anderson J, Childs B, et al.: Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013;36:1384-1395.
27. Chase HP, Doyle FJ III, Zisser H, et al.: Multicenter closedloop/hybrid meal bolus insulin delivery with type 1 diabetes. Diabetes Technol Ther 2014;16:623-632.
28. Heise T, Pieber TR, Danne T, et al.: Faster onset and greater early exposure and glucose lowering effect with faster-acting insulin aspart versus insulin aspart: a pooled analysis in subjects with type 1 diabetes. Diabetes 2016;65 (Suppl 1):A239.